Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.54 |
| ▸ | CCKBR | P32239 | 1/20 | 0.48 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 14/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MET | P08581 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1423370 | 0.84 | ACLY (0.53) | ACLYCCKBRHTR6PKMSMN1; SMN2 | |
| SCHEMBL1423661 | 0.77 | HTR6 (0.61) | HTR6ADRA2AHTR2C | |
| SCHEMBL1423386 | 0.77 | HTR6 (0.58) | HTR6ADRA2AHTR2C | |
| SCHEMBL1423219 | 0.77 | ACLY (0.56) | ACLYCCKBRHTR6HTR2C | |
| SCHEMBL1422633 | 0.76 | ACLY (0.58) | ACLYCCKBRHTR6PKMSMN1; SMN2 | |
| SCHEMBL1654040 | 0.76 | ACLY (0.47) | ACLYCCKBRHTR6ADRA2AHTR2C | |
| SCHEMBL1421966 | 0.76 | ACLY (0.56) | ACLYCCKBRHTR6PKMSMN1; SMN2 | |
| SCHEMBL14290796 | 0.76 | ACLY (0.56) | ACLYCCKBRHTR6PKMSMN1; SMN2 | |
| SCHEMBL10238843 | 0.75 | ACLY (0.52) | ACLYCCKBRHTR6PKMSMN1; SMN2 | |
| SCHEMBL10239535 | 0.75 | ACLY (0.50) | ACLYCCKBRHTR6PKMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105555-A1 | SUBSTITUTED N-IMIDAZO[2,1-B]THIAZOLE-5-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | LABORATORIOS DE. DR. ESTEVE, S.A. (ES) | 2011-05-05 | — | — | US | claimed |
| EP-2297166-A1 | SUBSTITUTED N-IMIDAZO[2,1-B]THIAZOLE-5-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-03-23 | — | — | EP | claimed |
| US-20110105555-A1 | SUBSTITUTED N-IMIDAZO[2,1-B]THIAZOLE-5-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | LABORATORIOS DE. DR. ESTEVE, S.A. (ES) | 2011-05-05 | — | — | US | disclosed |
| US-20110105555-A1 | SUBSTITUTED N-IMIDAZO[2,1-B]THIAZOLE-5-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | LABORATORIOS DE. DR. ESTEVE, S.A. (ES) | 2011-05-05 | — | — | US | disclosed |
| US-20110105555-A1 | SUBSTITUTED N-IMIDAZO[2,1-B]THIAZOLE-5-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | LABORATORIOS DE. DR. ESTEVE, S.A. (ES) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105555-A1 | SUBSTITUTED N-IMIDAZO[2,1-B]THIAZOLE-5-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | HTR6, HTR1A, HTR5A | ACLY 3936/4885CCKBR 41/4885NR3C1 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.